A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

NCT02142296 ·Status: COMPLETED ·Phase: PHASE4

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

NCT01918878 ·Status: UNKNOWN ·Phase: PHASE4

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept

NCT02125864 ·Status: COMPLETED ·Phase: PHASE4

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

NCT02581891 ·Status: COMPLETED ·Phase: PHASE4

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

NCT02157077 ·Status: COMPLETED ·Phase: PHASE3

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

NCT03521895 ·Status: COMPLETED

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

NCT03470103 ·Status: COMPLETED

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

NCT02246829 ·Status: COMPLETED ·Phase: PHASE4

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT03411941 ·Status: COMPLETED

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

NCT07235527 ·Status: RECRUITING

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

NCT04641234 ·Status: COMPLETED

Effect Aflibercept on Ocular Perfusion

NCT03804099 ·Status: COMPLETED ·Phase: PHASE4

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

NCT03382587 ·Status: COMPLETED

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

NCT05473715 ·Status: TERMINATED ·Phase: PHASE4

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

NCT02289924 ·Status: COMPLETED

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCT02540954 ·Status: COMPLETED ·Phase: PHASE3

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

NCT03290794 ·Status: COMPLETED

Aflibercept in Polypoidal Choroidal Vasculopathy

NCT02120950 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

NCT05155293 ·Status: COMPLETED ·Phase: PHASE3

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

NCT04270747 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

NCT06398080 ·Status: WITHDRAWN

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

NCT01914380 ·Status: COMPLETED

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

NCT02615496 ·Status: COMPLETED

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

NCT05345236 ·Status: COMPLETED ·Phase: PHASE3